Tian X J, Fang F, Ding C H, Ren X T, Wang X, Wang X F, Lyu J L, Jin H, Han T L, Deng J
Department of Neurology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China.
Zhonghua Er Ke Za Zhi. 2021 Dec 2;59(12):1059-1064. doi: 10.3760/cma.j.cn112140-20210430-00369.
To summarize the clinical characteristics of SYNGAP1-related epilepsy in children. Data of 13 patients with SYNGAP1 gene variants diagnosed with epilepsy at Department of Neurology, Beijing Children's Hospital were collected retrospectively from March 2017 to October 2020 and the patients were followed up. The clinical features, electroencephalogram(EEG), brain imaging, gene results and treatment were summarized. Twelve patients were followed up successfully among the 13 patients with SYNGAP1 variants. The last follow-up age was 5 years and 7 months (3 years and 1 month to 9 years).The onset age of seizures was 2 years (4 months to 3 years). Seizure types included eyelid myoclonia with or without absence (9 cases), myoclonic seizure (5 cases), atypical absence (4 cases), suspicious atonic seizures(4 cases),unclassified fall attack (6 cases), and the frequency of seizures varied from several times to more than 100 times per day. Four cases had the mimic phenotype of myoclonic astatic epilepsy. The seizures of 10 cases could be triggered by eating (5 cases), emotion (5 cases), fever (3 cases), voice (2 cases), fatigue (2 cases), etc. Electroencephalography (10 cases) showed interictal generalized or focal epileptiform discharges (9 cases), and atypical aphasia (4 cases), myoclonic seizure (2 cases) and eyelid myoclonic seizure (1 case) were monitored. Of the 12 cases, 9 were added with valproate, all of which were effective (the frequency of seizures reduced>50%). Five cases received combined levetiracetam, in 3 the treatments were effective. To last follow-up, 3 cases were seizure free from 6 months to 1 year and 1 month, but the remaining 7 cases still had seizures, one or several times per day. All 13 cases had developmental retardation (speech ability impaired mostly), 2 cases were severe, 10 cases were moderate, 1 case was mild. The SYNGAP1 gene variants of 13 patients were all de novo, including 12 variants. Among them, 4 were frameshift variants, 4 were nonsense variants, 2 were missense variants and 2 were splice site variants. Patients with SYNGAP1-related epilepsy have an early onset age and many seizure types. The main seizure type is eyelid myoclonia with or without absence, and other seizure types include myoclonic seizure, atypical absence, unclassified fall attack, etc. Valproate is effective in most patients, but seizures in some patients might be intractable. Most patients have developmental delay (mainly moderate and severe), speech ability impaired mostly.
总结儿童SYNGAP1相关癫痫的临床特征。回顾性收集2017年3月至2020年10月在北京儿童医院神经科确诊为癫痫的13例携带SYNGAP1基因变异的患者资料,并对患者进行随访。总结其临床特征、脑电图、脑影像学、基因检测结果及治疗情况。13例携带SYNGAP1变异的患者中,12例获得成功随访。末次随访年龄为5岁7个月(3岁1个月至9岁)。癫痫起病年龄为2岁(4个月至3岁)。发作类型包括伴或不伴失神的眼睑肌阵挛(9例)、肌阵挛发作(5例)、非典型失神发作(4例)、可疑失张力发作(4例)、未分类跌倒发作(6例),发作频率从每日数次至100余次不等。4例具有肌阵挛失张力癫痫的拟表型。10例患者的发作可由进食(5例)、情绪(5例)、发热(3例)、声音(2例)、疲劳(2例)等诱发。脑电图检查(10例)显示发作间期广泛性或局灶性癫痫样放电(9例),监测到非典型失语(4例)、肌阵挛发作(2例)和眼睑肌阵挛发作(1例)。12例患者中,9例加用丙戊酸盐,均有效(发作频率降低>50%)。5例联合使用左乙拉西坦,3例治疗有效。至末次随访时,3例患者无发作6个月至1年1个月,但其余7例仍有发作,每日发作1次或数次。13例患者均有发育迟缓(主要为语言能力受损),2例严重,10例中度,1例轻度。13例患者的SYNGAP1基因变异均为新发,共12种变异类型。其中,4种为移码变异,4种为无义变异,2种为错义变异,2种为剪接位点变异。SYNGAP1相关癫痫患者起病年龄早,发作类型多样。主要发作类型为伴或不伴失神的眼睑肌阵挛,其他发作类型包括肌阵挛发作、非典型失神发作、未分类跌倒发作等。丙戊酸盐对大多数患者有效,但部分患者的癫痫发作可能难以控制。大多数患者有发育迟缓(主要为中度和重度),主要为语言能力受损。